GeneDx Net Income From Continuing Ops from 2010 to 2026
| WGS Stock | 76.97 2.77 3.73% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -21 M | Current Value -22.1 M | Quarterly Volatility 139.6 M |
Check GeneDx Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GeneDx Holdings' main balance sheet or income statement drivers, such as Interest Income of 3.1 M, Depreciation And Amortization of 28.3 M or Interest Expense of 2.7 M, as well as many indicators such as Price To Sales Ratio of 6.07, Dividend Yield of 0.0 or PTB Ratio of 10.78. GeneDx financial statements analysis is a perfect complement when working with GeneDx Holdings Valuation or Volatility modules.
GeneDx | Net Income From Continuing Ops | Build AI portfolio with GeneDx Stock |
The evolution of Net Income From Continuing Ops for GeneDx Holdings Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how GeneDx Holdings compares to historical norms and industry peers.
Latest GeneDx Holdings' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of GeneDx Holdings Corp over the last few years. It is GeneDx Holdings' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GeneDx Holdings' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
GeneDx Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (94,346,826) | |
| Coefficient Of Variation | (147.99) | |
| Mean Deviation | 98,128,199 | |
| Median | (29,704,000) | |
| Standard Deviation | 139,619,569 | |
| Sample Variance | 19493.6T | |
| Range | 528M | |
| R-Value | (0.34) | |
| Mean Square Error | 18318.8T | |
| R-Squared | 0.12 | |
| Significance | 0.18 | |
| Slope | (9,537,756) | |
| Total Sum of Squares | 311898T |
GeneDx Net Income From Continuing Ops History
About GeneDx Holdings Financial Statements
GeneDx Holdings shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although GeneDx Holdings investors may analyze each financial statement separately, they are all interrelated. The changes in GeneDx Holdings' assets and liabilities, for example, are also reflected in the revenues and expenses on on GeneDx Holdings' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -21 M | -22.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.